There is no single, evidence-based lifespan for all stem cell treatments. Blood-forming stem cell transplants restore blood-cell production after intensive cancer treatment; their immune-recovery timelines are not an expiration date for the treatment’s benefit [1]. For Ryoncil, an approved treatment for a specific transplant complication in children, response was assessed at Day 28—not evidence that its effects end after 28 days [2]. For knee osteoarthritis injections, a large randomized trial found pain improvement at 12 months, but the cell treatments were not superior to corticosteroid injections [3].
The useful question is: how long did a measured benefit last with this exact product, for this condition, compared with another treatment? Recovery time, symptom relief, and repair of damaged tissue are different outcomes.

How Long Blood-Forming Transplant Benefits Last
A hematopoietic, or blood-forming, stem cell transplant is not the same treatment as a joint injection or a clinic’s cell infusion. In cancer care, it usually restores the body’s ability to make blood cells after high-dose chemotherapy, sometimes with radiation. Donor immune cells can also attack remaining leukemia cells. Whether the underlying disease stays controlled is a separate question from whether blood-cell production recovers [1].
Recovery Is Not a Benefit Expiration Date
NCI describes full immune recovery as taking several months after an autologous transplant, using your own cells, and 1 to 2 years after an allogeneic or identical-twin transplant. Those numbers describe recovery—not how long remission lasts or when transplanted cells stop working. Your transplant team must interpret disease control and recovery separately [1]. These timelines should not be applied to the different cell-treatment procedures offered in Japan.
Long-Term Follow-Up Still Matters
Transplant treatment can have long-term complications, including infertility, cataracts, secondary cancers, and liver, kidney, lung, or heart damage. Transplants using donor cells also carry a risk of graft-versus-host disease, in which donor immune cells attack the recipient’s tissues. Successful blood-cell recovery does not remove the need to monitor these problems [1].
What Ryoncil’s Day-28 Results Mean
On December 18, 2024, the FDA approved Ryoncil (remestemcel-L-rknd), made from donor bone-marrow mesenchymal stromal cells, or MSCs. Its indication is steroid-refractory acute graft-versus-host disease in children aged 2 months and older—not arthritis, general rejuvenation, or routine pain relief [2].
The multicenter, single-arm study included 54 children. The initial course was eight intravenous infusions over four weeks. At Day 28, 16 of 54 children had a complete response (30%) and 22 had a partial response (41%). Participants with partial or mixed responses received additional weekly infusions for four weeks. These were disease-response results, not a universal treatment schedule for other conditions [2].
Day 28 is an assessment point, not a measured maximum duration of benefit. The FDA announcement describes response rate and duration as evidence supporting approval; the Day-28 percentages alone cannot tell you how long an individual child will remain improved. The study had no concurrent comparison group, and its results cannot establish the durability of a different MSC product [2].
How Long Knee Injection Effects Last
For knee osteoarthritis, “improvement lasted a year” does not necessarily mean “the cells provided a year of extra benefit.” The MILES trial, published in 2023, illustrates the difference. This U.S. multicenter, randomized, single-blind phase 2/3 study randomized 480 people with radiographic knee osteoarthritis of Kellgren–Lawrence grades II–IV; its abstract reports a primary-endpoint analysis of 440 patients [3].
The trial compared injections into the knee joint using three preparations: the patient’s own bone-marrow aspirate concentrate, their own adipose stromal vascular fraction, and donor umbilical-cord-tissue-derived MSCs. The comparator was a corticosteroid injection. These are distinct preparations; marrow concentrate and stromal vascular fraction are mixed-cell products, not interchangeable with a manufactured MSC product [3].
All groups improved from baseline, with improvement sustained at one year. However, none of the cell treatments was superior to corticosteroid on the two primary pain measures at 12 months: a visual analog scale and the Knee injury and Osteoarthritis Outcome Score pain scale. No group showed a significant improvement in the MRI osteoarthritis score from baseline. The study therefore does not establish an additional year of benefit from the cells or demonstrate cartilage repair [3].
No procedure-related serious adverse events were reported during the study, but joint swelling, bruising, and hematomas did occur. That safety finding applies to the studied procedures and observation period; it does not prove that every clinic product is safe. Likewise, this trial does not settle the effectiveness or duration of every possible cell preparation [3].
Duration Evidence at a Glance
| Treatment | Measured timeline | What it does not establish |
|---|---|---|
| Blood-forming transplant in cancer care | Immune recovery: several months with own cells; 1 to 2 years with donor or identical-twin cells [1]. | These are not remission durations or treatment expiration dates. |
| Ryoncil for pediatric steroid-refractory acute graft-versus-host disease | Day-28 complete response 30% and partial response 41% in 54 children [2]. | The assessment day does not mean benefit ends that day. |
| Three knee cell preparations in MILES | Pain outcomes assessed at 12 months; no superiority over corticosteroid [3]. | Improvement from baseline does not establish a cell-specific advantage or cartilage repair. |
What Japanese Approval Records Tell You
Japan’s product records provide examples of narrowly defined uses. PMDA records TEMCELL HS Inj.’s September 18, 2015 approval for acute graft-versus-host disease after donor transplantation. It also records STEMIRAC Inj.’s December 28, 2018 conditional, time-limited approval for neurological symptoms and functional disorders associated with traumatic spinal cord injury, restricted to ASIA Impairment Scale grades A, B, or C. Both use bone-marrow-derived MSCs intravenously, but TEMCELL uses donor cells and STEMIRAC uses the patient’s own cells [4].
These dated approvals do not tell you how many months a patient’s improvement will last. Nor should a historical conditional approval be read as confirmation of a product’s present authorization or availability. Before treatment, ask the provider to identify the current authorization, its conditions, and the evidence for the proposed use.
Japan’s medical-practice framework under the Act on the Safety of Regenerative Medicine is distinct from commercial product approval under the PMD Act. Compliance with one framework must not be presented as product approval under the other, or as proof of how long a benefit lasts [5].
Do Effects Wear Off or Require Repeat Treatment?
Osteoarthritis involves joint tissues breaking down over time, and its course differs from person to person. A period of less joint pain does not by itself show that joint damage has been repaired [6]. In MILES, pain improvement and the lack of significant MRI improvement were separate findings [3].
The studies discussed here do not establish a universal six-month or annual “top-up” schedule for clinic injections. Before agreeing to another session, ask what changed after the first treatment, whether improvement was measured, and what evidence supports repeating that exact product. A repeat schedule used for pediatric graft-versus-host disease cannot justify repeat injections for knee pain.
How Long Do Risks Need Monitoring?
FDA reports of harm from unapproved regenerative medicine products include blindness, infections, and tumor formation. Its safety concerns also include unwanted immune responses and cells forming unintended tissue. These reports do not supply a single complication rate for all products, but they are reasons not to interpret an uneventful first month as proof of long-term safety [7].
Approved products have risks too. For Ryoncil, common adverse reactions included infections, fever, bleeding, swelling, abdominal pain, and hypertension; the FDA also warns about hypersensitivity, acute infusion reactions, infection transmission, and ectopic tissue formation. Treatment requires appropriate premedication and monitoring [2].
Before travel or payment, ask who will handle complications after you return home, how long follow-up continues, and how to obtain your treatment records. Discuss indications and contraindications with the treating physician; a website’s safety overview cannot replace a product-specific risk discussion.
How to Check a Clinic’s Duration Claim
Suppose a clinic tells you, “Patients were better at 12 months.” Ask whether that means they improved compared with their starting point or did better than a comparison group. MILES shows why the distinction matters: improvement at one year did not establish superiority over corticosteroid [3]. A treatment being listed in a trial registry is not a substitute for reading its results.
| Ask for | What to check |
|---|---|
| The exact product and procedure | Cell source, preparation, dose, injection route, and number of sessions—not just “stem cells.” |
| A matching patient population | Your diagnosis and disease severity, not results from another condition. |
| A defined outcome | Pain, walking ability, disease response, or tissue change; do not treat them as equivalent. |
| The comparator and trial phase | Was it an early safety study or a controlled efficacy trial? Comparison groups help distinguish a treatment effect from other changes [8]. |
| Follow-up and missing results | How many people started, how many were assessed later, and what happened to those who dropped out? |
| Repeat-treatment and safety data | How many needed more treatment, whether their improvement lasted, and what harms were recorded. |
For your own follow-up, agree on the same measure before and after treatment—for example, a named pain scale and a specific walking task. Record changes in medication, rehabilitation, and additional injections alongside it. This can make a consultation more useful, but a personal symptom diary cannot establish that cells caused an improvement.
Considering treatment in Japan?
Use the contact form to ask about the proposed procedure, its evidence, and follow-up arrangements before making a decision. Avoid sending sensitive medical records until secure submission instructions are provided.
Ask About Treatment and Follow-UpThe Bottom Line
Do not accept one “lasts X years” answer for every stem cell treatment. Transplant recovery is not the same as lasting disease control, Ryoncil’s Day-28 response is not a 28-day expiration date, and the knee preparations in MILES did not outperform corticosteroid at 12 months. Ask for the exact product, a meaningful comparison, the measured outcome, and the follow-up period before judging a duration claim [1] [2] [3].
This article provides general information, not personal medical advice. It does not report patient outcomes from this website or its service providers. A qualified treating physician should assess the evidence and risks for the exact treatment proposed.
References
- National Cancer Institute. Stem Cell Transplants in Cancer Treatment. United States; accessed November 12, 2026. Applies to blood-forming transplantation in cancer care, not routine clinic injections.
- U.S. Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. December 18, 2024; United States; accessed November 12, 2026. Ryoncil’s pediatric indication, single-arm study, response results, dosing, and risks.
- Mautner K, et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nature Medicine, 2023. U.S. multicenter study; accessed November 12, 2026. Original research hosted by NIH/NLM, not an NIH endorsement. Findings apply to the tested preparations and 12-month outcomes. The author correction adds missing baseline pain rows to Table 1.
- Pharmaceuticals and Medical Devices Agency. List of Approved Regenerative Medical Products. Japan; accessed November 12, 2026. Historical approval entries and restricted indications for TEMCELL and STEMIRAC; not evidence of a common duration of benefit.
- Pharmaceuticals and Medical Devices Agency. Regenerative Medical Products. Japan; accessed November 12, 2026. Distinguishes medical-practice regulation under ASRM from product commercialization under the PMD Act.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoarthritis. United States; accessed November 12, 2026. Disease overview, not evidence for cell-treatment effectiveness.
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. United States; accessed November 12, 2026. Reported harms and safety concerns about unapproved products; not a universal adverse-event rate.
- National Cancer Institute. What Are Clinical Trials?. United States; accessed November 12, 2026. Trial design and comparison groups, not proof that a particular cell treatment works.




